Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating
(MT Newswires covers equity, commodity and economic research from major banks and research firms in
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
© 1999-2025 Midnight Trader, Inc. All rights reserved.

Related News
-
PRESS DIGEST- New York Times business news - April 1
Reuters - 16 minutes ago
-
OpenAI plans to release open-weight language model in coming months
Reuters - 20 minutes ago
-
In Myanmar's 'Abode of Kings', earthquake hits home of military power
Reuters - 21 minutes ago
-
Reuters - 22 minutes ago
-
BRIEF-Iberdrola Sells Maine Natural Gas For Nearly $90 Mln To Unitil
Reuters - 37 minutes ago
-
âBecton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports
Reuters - 39 minutes ago
-
Taiwan coast guard warns of China using 'pretext' to launch war games this year
Reuters - 39 minutes ago
-
Sony reveals cast for four 'bingeable' movies about The Beatles
Reuters - 39 minutes ago